feed,title,long_url,short_url
Benzinga,Exelixis' Cabozantinib Shows Overall Objective Response Rates of 38% In Genitourinary Tumor Settings,https://www.benzinga.com/general/biotech/21/02/19674079/exelixis-cabozantinib-shows-overall-objective-response-rates-of-38-in-genitourinary-tumor-setting,https://j.mp/2OL4vBF
Benzinga,Ceylon Graphite to Re-Start Production at K1 Mine and Provides Operational Update,https://www.benzinga.com/pressreleases/21/02/g19674958/ceylon-graphite-to-re-start-production-at-k1-mine-and-provides-operational-update,https://j.mp/2NtRonK
Benzinga,Reading Plus Announces Virtual Presentations on Building Student Silent Reading Skills,https://www.benzinga.com/pressreleases/21/02/g19674831/reading-plus-announces-virtual-presentations-on-building-student-silent-reading-skills,https://j.mp/3b9RQQd
Benzinga,LinearB and Clubhouse Partner to Help Dev Teams Continuously Improve Software Project Delivery,https://www.benzinga.com/pressreleases/21/02/n19674815/linearb-and-clubhouse-partner-to-help-dev-teams-continuously-improve-software-project-delivery,https://j.mp/2Oy1Gnh
Benzinga,LinearB and Clubhouse Partner to Help Dev Teams Continuously Improve Software Project Delivery,https://www.benzinga.com/pressreleases/21/02/n19674813/linearb-and-clubhouse-partner-to-help-dev-teams-continuously-improve-software-project-delivery,https://j.mp/3qqcqCv
Benzinga,"Exelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer",https://www.benzinga.com/general/biotech/21/02/19670150/exelixis-cabozantinib-data-shows-clinically-significant-benefit-versus-pfizers-sutent-in-a-type-o,https://j.mp/3b8F8Bj
